According to the Complaint, Immunomedics, Inc. is a leader in next-generation antibody-drug conjugate (“ADC”) technology, committed to helping people with hard-to-treat cancers.
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.